IV Iron Risks and Low-Dose AML Gains
About this episode
This episode features discussions on the risks of IV iron and the benefits of a low-dose regimen for AML treatment.
In this week's episode, Blood editor Dr. James Griffin interviews Drs. Heinz Zoller and Raul Ribeiro on their latest articles published in Blood . Dr. Zoller discusses " Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia ", and how these findings support consideration of alternative IV iron formulations that provide similar efficacy without risk of skeletal complications. Dr. Ribeiro discusses " A low-versus standard-dose regimen an induction for AML: a multicenter, randomized noninferiority trial " and how the low-dose regimen is associated with fewer toxicities, faster hematologic recovery, and reduced health care costs, suggesting a feasible treatment strategy for resource-limited settings.
More episodes of Blood Podcast
- IV Iron during Acute Infection and Revisiting iTTP Refractoriness
- A Pediatric ITP Risk Model and Targeting CD2 with CAR T-cell therapies
- Orca-T for GVHD–free survival and Understanding VEXAS anemia
- Treating AML, Before and After Relapse
Explore listener stats, chart rankings, contacts and more on the Blood Podcast podcast page.